BMS nabs approval for first-line kidney cancer combo

Apr 17, 2018

Bristol-Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) combo was approved by the U.S. Food and Drug Administration as the first Immuno-Oncology combination therapy for previously untreated patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).

In the Phase 3 CheckMate -214 clinical trial, the combination demonstrated a significant increase in overall survival in the patient population compared to a current standard of care, sunitinib. An OS benefit was observed regardless of PD-L1 expression level. In the CheckMate -214 trial, which used dosing optimized for advanced renal cell carcinoma, Opdivo + Yervoy was associated with fewer overall Grade 3 or 4 adverse reactions than sunitinib.

Read the full BMS release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments